250 related articles for article (PubMed ID: 26681820)
1. Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy.
Miyata Y; Sakai H
Dis Markers; 2015; 2015():857416. PubMed ID: 26681820
[TBL] [Abstract][Full Text] [Related]
2. BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).
Hayne D; Stockler M; McCombie SP; Chalasani V; Long A; Martin A; Sengupta S; Davis ID
BMC Cancer; 2015 May; 15():432. PubMed ID: 26014129
[TBL] [Abstract][Full Text] [Related]
3. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer.
Arends TJ; van der Heijden AG; Witjes JA
J Urol; 2014 Sep; 192(3):708-13. PubMed ID: 24704017
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
5. Intravesical electro-osmotic administration of mitomycin C.
Di Stasi SM; Verri C; Celestino F; De Carlo F; Pagliarulo V
Urologia; 2016 Oct; 83(Suppl 2):18-23. PubMed ID: 27716887
[TBL] [Abstract][Full Text] [Related]
6. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
7. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R
J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
[TBL] [Abstract][Full Text] [Related]
8. The role of hyperthermia as a treatment for non-muscle invasive bladder cancer.
Bahouth Z; Halachmi S; Moskovitz B; Nativ O
Expert Rev Anticancer Ther; 2016; 16(2):189-98. PubMed ID: 26618756
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy.
Wosnitzer MS; Domingo-Domenech J; Castillo-Martin M; Ritch C; Mansukhani M; Petrylack DP; Benson MC; McKiernan JM; Cordon-Cardo C
J Urol; 2011 Nov; 186(5):2094-100. PubMed ID: 21944130
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
Seo HK; Cho KS; Chung J; Joung JY; Park WS; Chung MK; Lee KH
Urology; 2010 Aug; 76(2):512.e1-7. PubMed ID: 20579709
[TBL] [Abstract][Full Text] [Related]
11. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.
Nielsen ME; Smith AB; Pruthi RS; Guzzo TJ; Amiel G; Shore N; Lotan Y
BJU Int; 2012 Oct; 110(7):967-72. PubMed ID: 22487336
[TBL] [Abstract][Full Text] [Related]
12. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
Ajili F; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
[TBL] [Abstract][Full Text] [Related]
14. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases.
Lee CT; Barocas D; Globe DR; Oefelein MG; Colayco DC; Bruno A; O'Day K; Bramley T
J Urol; 2012 Dec; 188(6):2114-9. PubMed ID: 23083857
[TBL] [Abstract][Full Text] [Related]
15. Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage.
Fankhauser CD; Teoh JY; Mostafid H
Curr Opin Urol; 2020 May; 30(3):365-369. PubMed ID: 32141939
[TBL] [Abstract][Full Text] [Related]
16. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
[TBL] [Abstract][Full Text] [Related]
17. Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer.
Yokomizo A; Kanimoto Y; Okamura T; Ozono S; Koga H; Iwamura M; Tanaka H; Takahashi S; Tsushima T; Kanayama HO; Akaza H; Shinohara N; Mugiya S; Nomata K; Nakamura T; Naito S
J Urol; 2016 Jan; 195(1):41-6. PubMed ID: 26307162
[TBL] [Abstract][Full Text] [Related]
18. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer.
Hendricksen K; Witjes JA
Curr Opin Urol; 2007 Sep; 17(5):352-7. PubMed ID: 17762630
[TBL] [Abstract][Full Text] [Related]
19. [Intravesical instillations in non-muscle-invasive bladder cancer (NMIBC). Prospects for thermochemotherapy].
Irani J
Prog Urol; 2016 Nov; 26(14):860-864. PubMed ID: 27712914
[TBL] [Abstract][Full Text] [Related]
20. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.
Halachmi S; Moskovitz B; Maffezzini M; Conti G; Verweij F; Kedar D; Sandri SD; Nativ O; Colombo R
Urol Oncol; 2011; 29(3):259-64. PubMed ID: 19395285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
